Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 24.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 429,513 shares of the biopharmaceutical company's stock after buying an additional 84,801 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.48% of Chimerix worth $1,495,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bender Robert & Associates bought a new position in Chimerix during the fourth quarter valued at approximately $37,000. Stoneridge Investment Partners LLC lifted its stake in shares of Chimerix by 22.5% in the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company's stock valued at $154,000 after purchasing an additional 8,134 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new stake in shares of Chimerix in the 4th quarter valued at approximately $183,000. Palumbo Wealth Management LLC bought a new stake in shares of Chimerix in the 4th quarter valued at approximately $221,000. Finally, Valeo Financial Advisors LLC lifted its stake in shares of Chimerix by 78.8% in the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock valued at $509,000 after purchasing an additional 64,420 shares during the last quarter. 45.42% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 20,760 shares of company stock worth $91,175 in the last ninety days. 13.10% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
CMRX has been the subject of several analyst reports. StockNews.com initiated coverage on Chimerix in a research note on Sunday. They issued a "hold" rating for the company. Wedbush reaffirmed a "neutral" rating and issued a $8.55 price objective (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.50 price objective (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $8.55 price objective (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th.
View Our Latest Research Report on CMRX
Chimerix Trading Up 0.4 %
Shares of NASDAQ CMRX traded up $0.03 during midday trading on Friday, hitting $8.50. The company's stock had a trading volume of 3,191,974 shares, compared to its average volume of 2,102,605. The business's 50 day moving average is $5.34 and its two-hundred day moving average is $2.84. Chimerix, Inc. has a 12-month low of $0.75 and a 12-month high of $8.52. The firm has a market cap of $764.46 million, a P/E ratio of -9.04 and a beta of 0.32.
Chimerix (NASDAQ:CMRX - Get Free Report) last issued its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million during the quarter, compared to analysts' expectations of $0.31 million. On average, analysts predict that Chimerix, Inc. will post -0.99 earnings per share for the current fiscal year.
Chimerix Company Profile
(
Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Recommended Stories
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
